lncRNA SNHG20表达与乳腺癌放疗敏感性及预后的关系

doi:10.3969/j.issn.1006-6233.2020.10.015

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1242 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 通过检测lncRNA SNHG20在乳腺癌组织及正常乳腺组织中表达水平,分析其与乳腺癌放疗敏感性及患者预后关系。方法: 选取2013年11月至2016年10月本院收治的乳腺癌患者119例作为研究对象,收集其活检癌组织,另选取同期本院病理库留存的正常乳腺组织119例作为对照。实时荧光定量(qRT-PCR)检测lncRNA SNHG20表达水平,并分析与乳腺癌患者临床病理特征、放疗敏感性关系,Cox回归模型分析乳腺癌患者预后独立危险因素。结果: 乳腺癌组织中lncRNA SNHG20表达水平显著高于正常乳腺组织(P<0.05)。乳腺癌组织中lncRNA SNHG20表达水平与分化程度、TNM分期、淋巴结转移及辅助化疗有关(P均<0.05)。lncRNA SNHG20高表达组患者放疗后缓解率显著低于lncRNA SNHG20低表达组患者(P<0.05)。lncRNA SNHG20高表达组患者3年总生存率明显低于lncRNA SNHG20低表达组(P<0.05)。TNM分期Ⅲ期、淋巴结转移、lncRNA SNHG20高表达是影响乳腺癌患者不良预后独立危险因素(P均<0.05)。结论: lncRNA SNHG20在乳腺癌组织中高表达,与乳腺癌放疗敏感性低、TNM分期、淋巴结转移及患者总生存率有关,可能作为乳腺癌放疗敏感性及患者预后标志物,为提高乳腺癌临床治疗疗效及改善患者预后提供一定理论依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	文兰香
	覃世运
	陈丽君

关键词 ： lncRNA SNHG20, 乳腺癌, 放疗敏感性

Abstract：Objective: To detect the expression of lncRNA SNHG20 in breast cancer and normal breast tissue, and to analyze its relationships with radiosensitivity and prognosis of breast cancer. Methods: 119 patients with breast cancer admitted to our hospital from November 2013 to October 2016 were selected as the research objects, with their biopsy cancer tissue being collected, and 119 normal breast tissues retained in our hospital pathological database during the same period were selected as the control group. Real-time fluorescence quantitative (qRT-PCR) was used to detect the expression of lncRNA SNHG20, and then its association with clinicopathological characteristics and radiosensitivity of breast cancer patients were analyzed. Cox regression model was used to analyze the independent risk factors for prognosis of breast cancer patients. Results: The expression level of lncRNA SNHG20 in breast cancer tissue was significantly higher than that in normal breast tissue (P<0.05). The expression of lncRNA SNHG20 in breast cancer tissues was correlated with differentiation, TNM stage, lymph node metastasis and adjuvant chemotherapy (all P<0.05). The remission rate of patients with high expression of lncRNA SNHG20 after radiotherapy was significantly lower than that of patients with low expression of lncRNA SNHG20 (P<0.05). The 3-year overall survival rate of patients with high expression of lncRNA SNHG20 was significantly lower than that of patients with low expression of lncRNA SNHG20 (P<0.05). TNM stage III, lymph node metastasis and high expression of lncRNA SNHG20 were independent risk factors for poor prognosis of breast cancer patients (all P<0.05). Conclusion: LncRNA SNHG20 is highly expressed in breast cancer, and is related to low radiosensitivity, TNM stage, lymph node metastasis and overall survival rate of breast cancer patients. It may be a marker of radiosensitivity and prognosis of breast cancer, and provide a theoretical basis for improving the clinical efficacy and prognosis of breast cancer patients.

Key words： lncRNA SNHG20 Breast cancer Radiosensitivity

基金资助:海南省卫生计生行业科研项目,(编号:17A200034)

引用本文:

文兰香, 覃世运, 陈丽君. lncRNA SNHG20表达与乳腺癌放疗敏感性及预后的关系[J]. 河北医学, 2020, 26(10): 1647-1651.
WEN Lanxiang, QIN Shiyun, CHEN Lijun. The Association Between the Expression of lncRNA SNHG20 and Radiosensitivity Prognosis of Breast Cancer. HeBei Med, 2020, 26(10): 1647-1651.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2020.10.015 或 http://www.hbyxzzs.cn/CN/Y2020/V26/I10/1647

[1] Valcourt DM, Dang MN, Day ES, et al. IR820-loaded PLGA nanoparticles for photothermal therapy of triple-negative breast cancer[J].Biomed Mater Res A, 2019, 107(8): 1702~1712.
[2] 陈偲晔,唐玉,宋永文,等.乳腺癌保乳治疗的疗效及预后[J].中华肿瘤杂志,2018,40(8):619~625.
[3] 魏世鸿, 陶娜, 欧阳水根, 等. 左侧乳腺癌根治术后IMRT和3D-CRT放疗技术剂量学比较[J]. 中华肿瘤防治杂志, 2019, 26(12): 855~860.
[4] Guo H, Yang S, Li S, et al. LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer[J]. Biomed Pharmacother, 2018, 102(1): 749~757.
[5] Wang B, Li X, Hu W, et al. Silencing of lncRNA SNHG20 delays the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma via regulating liver Kupffer cells polarization[J]. Iubmb Life, 2019, 71(12): 1952~1961.
[6] Cserni G, Chmielik E, Cserni B, et al. The new TNM-based staging of breast cancer[J]. Virchows Arch, 2018, 472(5):697~703.
[7] Kazuhiro K, Yasuo M, Toshiko Y, et al. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0[J]. Nagoya Med Sci, 2018, 80(2): 183~197.
[8] Wu X, Xiao Y, Zhou Y, et al. IncRNA SNHG20 promotes prostate cancer migration and invasion via targeting the miR-6516-5p/SCGB2A1 axis[J]. Am Transl Res, 2019,11(8): 5162~5169.
[9] Zhenyao C, Xin C, Zhaoxia W. 17P long non-coding RNA SNHG20 promotes non-small cell lung cancer cell progression by silencing of P21 expression[J].Thorac Oncol, 2018,13(4):9~18.
[10] Yu Z, Wang G, Zhang C, et al. LncRNA SBF2-AS1 affects the radiosensitivity of non-small cell lung cancer via modulating microRNA-302a/MBNL3 axis[J]. Cell Cycle, 2020,19(3): 300~316.
[11] Lai Y, Chen Y, Lin Y, et al. Down-regulation of LncRNA CCAT1 enhances radiosensitivity via regulating miR-148b in breast cancer[J]. Cell Biol Int, 2018, 42(2): 227~236.
[12] Hu X, Ding D, Zhang J, et al. Knock down lncRNA HOTAIR sensitize breast cancer cells to ionizing radiation through activating miR-218[J]. Biosci Rep, 2019, 39(4):1~9.
[13] Gao P, Fan R, Ge T. SNHG20 serves as a predictor for prognosis and promotes cell growth in oral squamous cell carcinoma[J]. Oncol Lett, 2019, 17(1): 951~957.